Parnassus Investments LLC Acquires 111,843 Shares of Edwards Lifesciences Corporation $EW

Parnassus Investments LLC grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 23.6% in the fourth quarter, HoldingsChannel reports. The fund owned 586,760 shares of the medical research company’s stock after buying an additional 111,843 shares during the period. Parnassus Investments LLC’s holdings in Edwards Lifesciences were worth $50,021,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Level Four Advisory Services LLC lifted its position in Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after buying an additional 119 shares during the last quarter. Colonial Trust Co SC lifted its position in Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after purchasing an additional 120 shares during the last quarter. Evermay Wealth Management LLC lifted its position in Edwards Lifesciences by 4.0% in the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock valued at $282,000 after purchasing an additional 128 shares during the last quarter. Florida Trust Wealth Management Co lifted its position in Edwards Lifesciences by 1.5% in the fourth quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock valued at $751,000 after purchasing an additional 132 shares during the last quarter. Finally, McIlrath & Eck LLC lifted its position in Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after purchasing an additional 135 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of several recent research reports. Robert W. Baird boosted their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. BTIG Research boosted their price objective on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Evercore reiterated an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a research report on Friday, April 24th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $95.96.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 81,038 shares of company stock worth $6,683,255 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Price Performance

EW opened at $85.75 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $89.48. The stock has a market capitalization of $49.37 billion, a PE ratio of 45.61, a price-to-earnings-growth ratio of 2.16 and a beta of 0.87. The stock’s 50 day moving average price is $82.70 and its 200-day moving average price is $83.10.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the previous year, the firm earned $0.64 earnings per share. The business’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.